1. Home
  2. UFCS vs NBTX Comparison

UFCS vs NBTX Comparison

Compare UFCS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Fire Group Inc.

UFCS

United Fire Group Inc.

N/A

Current Price

$51.23

Market Cap

1.4B

Sector

Finance

ML Signal

N/A

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

N/A

Current Price

$32.70

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UFCS
NBTX
Founded
1946
2003
Country
United States
France
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
UFCS
NBTX
Price
$51.23
$32.70
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
★ $57.50
$54.24
AVG Volume (30 Days)
123.8K
★ 144.8K
Earning Date
11-03-2026
09-24-2026
Dividend Yield
★ 1.55%
N/A
EPS Growth
★ 87.45
N/A
EPS
★ 3.78
N/A
Revenue
★ $1,386,412,000.00
N/A
Revenue This Year
$15.24
N/A
Revenue Next Year
$19.13
$50.69
P/E Ratio
$13.71
★ N/A
Revenue Growth
★ 10.62
N/A
52 Week Low
$33.53
$19.14
52 Week High
$58.20
$57.14

Technical Indicators

Market Signals
Indicator
UFCS
NBTX
Relative Strength Index (RSI) 40.83 58.72
Support Level $48.44 $30.73
Resistance Level $55.12 $35.17
Average True Range (ATR) 2.17 1.84
MACD -0.73 0.56
Stochastic Oscillator 39.84 72.25

Price Performance

Historical Comparison
UFCS
NBTX

About UFCS United Fire Group Inc.

United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: